Yeong Hoon Kim, Tae-Yun Kim, Ji-Seon Park, Jin Suk Park, Jihoo Lee, Joungdae Moon, Chom-Kyu Chong, Ivan Neves Junior, Fernando Raphael Ferry, Hye-Jin Ahn, Lokraj Bhatt, Ho-Woo Nam
Korean J Parasitol 2019;57(3):283-290. Published online June 30, 2019
A rapid diagnostic test (RDT) kit was developed to detect non-structural protein 1 (NS1) of yellow fever virus (YFV) using monoclonal antibody. NS1 protein was purified from the cultured YFV and used to immunize mice. Monoclonal antibody to NS1 was selected and conjugated with colloidal gold to produce the YFV NS1 RDT kit. The YFV RDTs were evaluated for sensitivity and specificity using positive and negative samples of monkeys from Brazil and negative human blood samples from Korea. Among monoclonal antibodies, clones 3A11 and 3B7 proved most sensitive, and used for YFV RDT kit. Diagnostic accuracy of YFV RDT was fairly high; Sensitivity was 0.0% and specificity was 100% against Dengue viruses type 2 and 3, Zika, Chikungunya and Mayaro viruses. This YFV RDT kit could be employed as a test of choice for point-of-care diagnosis and large scale surveys of YFV infection under clinical or field conditions in endemic areas and on the globe.
Citations
Citations to this article as recorded by
Synthesis of Truncated DNA Aptamer and Its Application to an Electrochemical Biosensor Consisting of an Aptamer and a MXene Heterolayer for Yellow Fever Virus Nayeon Kwon, Siyun Lee, Moonbong Jang, Jin-Ho Lee, Chulhwan Park, Taek Lee BioChip Journal.2024; 18(1): 93. CrossRef
Challenges in Direct Detection of Flaviviruses: A Review Bruna de Paula Dias, Camila Cavadas Barbosa, Cyntia Silva Ferreira, Samara Mayra Soares Alves dos Santos, Orlando Alfredo Pineda Arrieta, Wellington Carvalho Malta, Maria Laura Maximiano Dias Gomes, Mariela Alves e Silva, Júlia de Matos Fonseca, Lysandro Pathogens.2023; 12(5): 643. CrossRef
A Chikungunya Virus Multiepitope Recombinant Protein Expressed from the Binary System Insect Cell/Recombinant Baculovirus Is Useful for Laboratorial Diagnosis of Chikungunya Leonardo Assis da Silva, Monique da Rocha Queiroz Lima, Brenda Rabello de Camargo, Dyeferson Kened da Silva Coelho Guimarães, Anabele Azevedo Lima Barbastefano, Raquel Curtinhas de Lima, Paulo Vieira Damasco, Rivaldo Venâncio da Cunha, Luiz José de Souza, Microorganisms.2022; 10(7): 1451. CrossRef
The effects of tyrosine kinase inhibitors (TKIs) were evaluated on growth inhibition of intracellular Toxoplasma gondii in host ARPE-19 cells. The number of tachyzoites per parasitophorous vacuolar membrane (PVM) was counted after treatment with TKIs. T. gondii protein expression was assessed by western blot. Immunofluorescence assay was performed using Programmed Cell Death 4 (PDCD4) and T. gondii GRA3 antibodies. The TKIs were divided into 3 groups; non-epidermal growth factor receptor (non-EGFR), anti-human EGFR 2 (anti-HER2), and anti-HER2/4 TKIs, respectively. Group I TKIs (nintedanib, AZD9291, and sunitinib) were unable to inhibit proliferation without destroying host cells. Group II TKIs (lapatinib, gefitinib, erlotinib, and AG1478) inhibited proliferation up to 98% equivalent to control pyrimethamine (5 ?M) at 20 μM and higher, without affecting host cells. Group III TKIs (neratinib, dacomitinib, afatinib, and pelitinib) inhibited proliferation up to 98% equivalent to pyrimethamine at 1-5 μM, but host cells were destroyed at 10-20 ?M. In Group I, TgHSP90 and SAG1 inhibitions were weak, and GRA3 expression was moderately inhibited. In Group II, TgHSP90 and SAG1 expressions seemed to be slightly enhanced, while GRA3 showed none to mild inhibition; however, AG1478 inhibited all proteins moderately. Protein expression was blocked in Group III, comparable to pyrimethamine. PDCD4 and GRA3 were well localized inside the nuclei in Group I, mildly disrupted in Group II, and were completely disrupted in Group III. This study suggests the possibility of a vital T. gondii TK having potential HER2/4 properties, thus anti-HER2/4 TKIs may inhibit intracellular parasite proliferation with minimal adverse effects on host cells.
Citations
Citations to this article as recorded by
Small molecule kinase inhibitor altiratinib inhibits brain cyst forming bradyzoites of Toxoplasma gondii Yeong Hoon Kim, Hye-Jin Ahn, Hwa Sun Kim, Ho-Woo Nam Journal of Microbiology.2025; 63(2): e2409001. CrossRef
The antimicrobial activity of innate host-directed therapies: A systematic review Tirosh Shapira, Matthew Christofferson, Yossef Av-Gay International Journal of Antimicrobial Agents.2024; 63(5): 107138. CrossRef
Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections Francesca Arrighi, Arianna Granese, Paola Chimenti, Paolo Guglielmi Expert Opinion on Therapeutic Patents.2023; 33(3): 211. CrossRef
Latent Toxoplasmosis among Breast Cancer Patients in Jahrom, South of Iran Marzeieh Haghbin, Salar Maani, Mohammad Aref Bagherzadeh, Ahmadreza Bazmjoo, Heshmatollah Shakeri, Ali Taghipour, Shahab Falahi, Azra Kenarkoohi, Milad Badri, Amir Abdoli, Mubashir Javed Mintoo International Journal of Breast Cancer.2023; 2023: 1. CrossRef
Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors Qidong Tang, Ting Peng, Jie Hu, Tao Zhang, Pengqin Chen, Daoxing Chen, Yunjie Wang, Lingfeng Chen, Linjiang Tong, Yi Chen, Hua Xie, Guang Liang European Journal of Medicinal Chemistry.2022; 233: 114249. CrossRef
Secretome Analysis of Host Cells Infected with Toxoplasma gondii after Treatment of Human Epidermal Growth Factor Receptor 2/4 Inhibitors Hye-Jung Kim, Hye-Jin Ahn, Hyeweon Kang, Jaehui Park, Seul gi Oh, Saehae Choi, Won-Kyu Lee, Ho-Woo Nam The Korean Journal of Parasitology.2020; 58(3): 249. CrossRef
First
Prev
